FDA.reportPublic FDA data

ADAMTS13, recombinant-krhn 1500 UNT Injection

RxCUI
2670293
RxNorm name
ADAMTS13, recombinant-krhn 1500 UNT Injection
Display name
ADAMTS13, recombinant-krhn 1500 UNT Injection
Full name
ADAMTS13, recombinant-krhn 1500 UNT Injection
Term type
SCD
Status
DailyMed mapping
Updated
2026-06-04 23:38:50

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125795ADZYNMAADAMTS13, recombinant-krhn351(a)Rx2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
ADZYNMAAPADAMTASE ALFATAKEDA PHARMACEUTICALS AMERICA, INC.22728e96-efa0-46c1-bdd1-ad89a796d5e32024-08-30Warnings, Adverse reactionsExact identifier
rxcui: 2670293

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
22728e96-efa0-46c1-bdd1-ad89a796d5e3ADAMTS13, recombinant-krhn 1500 UNT InjectionSCD6These highlights do not include all the information needed to use ADZYNMA safely and effectively. See full prescribing information for ADZYNMA. ADZYNMA (ADAMTS13, recombinant-krhn) lyophilized powder for Injection, for intravenous use Initial U.S. Approval: 202320240830
22728e96-efa0-46c1-bdd1-ad89a796d5e3ADAMTS13, recombinant-krhn 1500 UNT InjectionPSN6These highlights do not include all the information needed to use ADZYNMA safely and effectively. See full prescribing information for ADZYNMA. ADZYNMA (ADAMTS13, recombinant-krhn) lyophilized powder for Injection, for intravenous use Initial U.S. Approval: 202320240830